EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
复制标题
DOI：
10.3892/or_00000238
复制
发表时间：
2009-02-01
期刊：
影响因子：
4.2
通讯作者：
Uchida, Ken
中科院分区：
文献类型：
--
作者：
Nogi, Hiroko;Kobayashi, Tadashi;Uchida, Ken
我们回顾性分析了表皮生长因子受体（EGFR）的表达作为一个预后指标，以预测乳腺癌亚型的新辅助化疗反应和生存。我们用免疫组化的方法对患者进行分型。采用免疫组织化学法测定EGFR表达。所有患者术前均接受以蒽环类药物为基础的方案。93例患者还接受了多西他赛治疗。在117名接受检测的患者中，28名（24%）为三阴性乳腺癌（TNBC），73名（62%）为激素受体阳性（管腔）亚型。在TNBC患者中，观察到EGFR表达的发生率显著较高（50%），（P=0.002），EGFR表达与化疗反应较差有关（P=0.03）和较差的生存率（P=0.17）;相反，在管腔亚型患者中，EGFR阳性表达与良好的临床反应（P=0.06）和较好的生存期（P=0.11）相关。这项回顾性分析表明，EGFR表达可能代表TNBC患者的不良预后标志物，并可能为TNBC患者选择适当的治疗方案提供有价值的工具。
We retrospectively analyzed the expression of epidermal growth factor receptor (EGFR) as a prognostic marker to predict neoadjuvant chemotherapy response and survival among breast cancer subtypes. We used immunohistochemical profiles to subtype the patients. EGFR expression was determined using immunohistochemistry. All patients received an anthracycline-based regimen preoperatively. Ninety-three patients also received docetaxel. Of the 117 patients tested, 28 (24%) were triple-negative breast cancer (TNBC) and 73 (62%) were hormone receptor-positive (luminal) subtype. Among the TNBC patients, a significantly higher incidence of EGFR expression (50%) was observed (P=0.002), and EGFR expression was related to a less favorable response to chemotherapy (P=0.03) and poorer survival (P=0.17); in contrast, among the luminal subtype patients, positive EGFR expression was related to a favorable clinical response (P=0.06) and better survival (P=0.11). This retrospective analysis demonstrated that EGFR expression may represent an adverse prognostic marker in patients with TNBC and may provide a valuable tool for selecting appropriate treatment regimens for patients with TNBC.